On November 3, 2023, Knowledge Ecology International (KEI) and Public Citizen (PC) submitted joint comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses” (88 FR… Continue Reading
On September 2, 2020, Knowledge Ecology International (KEI) sent a letter to the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential failure by Moderna, Inc. to disclose federal funding in patents supported by BARDA. KEI requested information concerning… Continue Reading
KEI Research Note 2020:2 Role of Private Sector, Governments and Charities in Funding Research and Development Related to Tocilizumab Luis Gil Abinader, May 28, 2020. From the Introduction: The funding of R&D for tocilizumab can be described as having three… Continue Reading
On April 29, 2020, the United States Trade Representative (USTR) published its annual Special 301 Report. A PDF copy of the report is available here. KEI has compiled copies of the Special 301 Report for every year since its inception… Continue Reading
On April 6, 2020, the Director-General of the World Health Organization (WHO), Dr. Tedros Ghebreyesus, gave a media briefing on COVID-19 and the WHO’s efforts to combat the pandemic. In his remarks, Dr. Tedros specifically highlighted the proposal by the… Continue Reading
On April 6, 2020, KEI received a response from the National Institutes of Health (NIH) to a letter we sent to DHHS Secretary Alex Azar on March 13, 2020 regarding three areas in Section 202 of the Bayh-Dole Act that… Continue Reading
March 27, 2020. We are writing to ask the WHO and its Member States to support the proposal by Costa Rica for the creation of a global pooling mechanism for rights in the data, knowledge and technologies useful in the… Continue Reading
Below are Freedom of Information Act (FOIA) requests filed by KEI related to issues concerning the coronavirus/COVID-19 pandemic. This page will be updated as we file requests and receive responses. Department of Health and Human Services Centers for Disease… Continue Reading
On Monday March 23, 2020, Gilead Sciences’ remdesivir received orphan designation from the US Food and Drug Administration (FDA) for the treatment of COVID-19. Remdesivir has been reported to be one of the candidates to potentially treat COVID-19, which the… Continue Reading
A House coronavirus stimulus bill contains a provision concerning the use of Other Transactions Authority to fund COVID-19 diagnostics. The provision appears to authorize the Department of Homeland Security (DHS) to award $2.2 billion to private sector companies to develop… Continue Reading